Shares are getting gobbled up pretty quickly; lots of demand here. I guess people like the story. So far, I'm going to go with culleraa's suggestion that it might be a quick out for the shorts. If this thing closes green, look out on the upside.
Sangamo Therapeutics, Inc. (SGMO) Short Interest � Find short interest for Sangamo Therapeutics, Inc. and all the companies you research at NASDAQ.com
Interesting timing here: doing it from a position of relative strength. We will soon see if this is a bigboys' deal to let the shorts out - in that case a small drop will be followed by a big move up. Some big names got their clients deep in the red with their wrong calls 6 m ago, so this is one way out. Most likely expln is the need to raise cash before the bear market - it will come. In this latter case no post-raise increase... Other explanations are biz development variety of course.
Here comes the dilution!
Hard to argue against the fact that that was a very strong response to the share offering.
public offering diluting this sucker. Hope the long term holders got out with some nice profits. This has been rumored for weeks.
Should I sell? bought all my stuff in the 3s & 4s might be a good time
Hope you all held through that brief down period. Ready for the next leg up?
Hey Paul and Thiepe, how do you like them apples? Lol...
Yahoo Finance Insights
SGMO reached a new 52 Week High at 8.70
Up $ 1.50 FRIDAY -i hope ? all the out Calls look good --$7.00 jan calls , cost a arm ? rocket in 90 days
I have stock and $7 Jan calls... :)
it got awfully quite in here
Shorts may have a little fun in the near future with this, but who knows. They are short-sighted, no pun intended. Think at least 7-8 months in the future and you won't worry about these price fluctuations. Think 2-3 years down the road and you'll see these dips as incredible buying opportunities.
Non-targeted mutations have been caused in mice by CRISPR. A possible advantage of ZFN is that two ZFNs need to come together to form the active dimer nuclease, which decreases the odds of non-target mutations compared to CRISPRs. IMHO
6.88... I have stock at $4 and $7 Jan calls...
Follow The Money
I think the timing was wrong for this secondary. Other opinions? I don't think they really need the money because of the Pfizer deal. What am I missing?
Wish I had more cash...
From 8K filling. "no more than 9,615,385 Shares will be sold at a price of not less than $7.80 per share, representing the last reported sale price of the Common Stock on the NASDAQ Global Select Market on May 25, 2017" Someone shorted over 500K shares on Friday expecting this will go down. I believe time to cover Next week. GLTA
This is nothing. no need to get panic. look at the pipeline. we are going higher.